The approval was based on data from the DAPA-CKD trial, which compared dapagliflozin, an SGLT2 inhibitor, to placebo on renal outcomes and cardiovascular mortality in patients with CKD.
The recall was initiated due to reports of stent fractures and endoleaks.
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
Telmisartan, an angiotensin II receptor blocker, is indicated for the treatment of hypertension.
Mavacamten is an oral, selective allosteric inhibitor of cardiac myosin.
AZD1222 utilizes a replication-deficient chimpanzee adenovirus to deliver a SARS-CoV-2 protein to induce a protective immune response.
Fully vaccinated individuals can visit with other fully vaccinated people, or unvaccinated people from a single household who are at low risk for severe COVID-19 disease, indoors without wearing masks or physical distancing.
The NIAID will evaluate the vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant, B.1.351.
The approval was based on data from the double-blind, parallel-group, active-controlled phase 3 PARAGON-HF trial.
To compare the clinical benefits of these diuretics, the study authors conducted a literature search that reported on outcomes such as MACE and left ventricular mass.
